146 related articles for article (PubMed ID: 6291832)
1. Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension.
Jackson B; McGrath BP; Johnston CI
Clin Exp Pharmacol Physiol Suppl; 1982; 7():99-104. PubMed ID: 6291832
[TBL] [Abstract][Full Text] [Related]
2. Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension.
Jackson B; Cubela R; Johnston CI
J Hypertens; 1984 Aug; 2(4):371-7. PubMed ID: 6099390
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
Laubie M; Schiavi P; Vincent M; Schmitt H
J Cardiovasc Pharmacol; 1984; 6(6):1076-82. PubMed ID: 6084763
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.
Biollaz J; Brunner HR; Gavras I; Waeber B; Gavras H
J Cardiovasc Pharmacol; 1982; 4(6):966-72. PubMed ID: 6185790
[TBL] [Abstract][Full Text] [Related]
5. Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report.
Karlberg BE; Fyhrquist F; Grönhagen-Riska C; Tikkanen I; Ohman KP
Scand J Urol Nephrol Suppl; 1984; 79():103-6. PubMed ID: 6089307
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421).
Sweet CS
Fed Proc; 1983 Feb; 42(2):167-70. PubMed ID: 6295819
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive peptides and hypertension: role of angiotensin converting enzyme.
Johnston CI; Iansek R; Millar JA; McGrath BP; Matthews PG
Aust N Z J Med; 1981; 11(Suppl 1):59-63. PubMed ID: 6266379
[TBL] [Abstract][Full Text] [Related]
8. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.
Johnston CI; Jackson B; McGrath B; Matthews G; Arnolda L
J Hypertens Suppl; 1983 Oct; 1(1):71-5. PubMed ID: 6100611
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension.
Azizi M; Guyene TT; Chatellier G; Ménard J
J Hypertens; 1994 Apr; 12(4):419-27. PubMed ID: 8064166
[TBL] [Abstract][Full Text] [Related]
10. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs.
McCaa RE; Gillespie JB
Fed Proc; 1984 Apr; 43(5):1336-41. PubMed ID: 6323226
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Wallis EJ; Ramsay LE; Hettiarachchi J
Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
[TBL] [Abstract][Full Text] [Related]
12. Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension.
Johnston CI; Jackson BJ; Larmour I; Cubella R; Casley D
Br J Clin Pharmacol; 1984; 18 Suppl 2(Suppl 2):233S-239S, 241S. PubMed ID: 6099738
[TBL] [Abstract][Full Text] [Related]
13. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
[TBL] [Abstract][Full Text] [Related]
14. [The acute effects of the new angiotensin I-converting enzyme inhibitor, enalapril maleate, on blood pressure, plasma renin, aldosterone and kinins in hypertensive patients].
Gotoh M; Mizuno K; Hashimoto S; Kunii N; Fukuchi S
Nihon Naibunpi Gakkai Zasshi; 1985 May; 61(5):619-29. PubMed ID: 2991035
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a vasodepressor effect of the angiotensin-converting enzyme inhibitor, MK421 (enalapril), independent of blockade of angiotensin II formation.
Wilkes BM
J Cardiovasc Pharmacol; 1984; 6(6):1036-42. PubMed ID: 6084759
[TBL] [Abstract][Full Text] [Related]
16. Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
Steele JL; Henik RA; Stepien RL
Vet Ther; 2002; 3(2):157-66. PubMed ID: 19750747
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin.
Brown NJ; Ryder D; Gainer JV; Morrow JD; Nadeau J
J Pharmacol Exp Ther; 1996 Nov; 279(2):703-12. PubMed ID: 8930174
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor.
Sweet CS; Gross DM; Arbegast PT; Gaul SL; Britt PM; Ludden CT; Weitz D; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):558-66. PubMed ID: 6259323
[No Abstract] [Full Text] [Related]
19. Acute hemodynamic and hormonal effects of MK-521 in congestive heart failure.
Dickstein K; Aarsland T; Woie L; Kremer D; Abrahamsen AM
Scand J Urol Nephrol Suppl; 1984; 79():125-7. PubMed ID: 6089311
[TBL] [Abstract][Full Text] [Related]
20. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
